EYEG

EyeGate Pharmaceuticals, Inc. [EYEG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EYEG Stock Summary

In the News

05:19 26 Feb 2024 EYEG

EYEG Stock Price: Why It Substantially Increased

The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) increased 22.95% in the previous trading session. This is why it happened.

10:20 26 Feb 2024 EYEG

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

01:55 26 Feb 2024 EYEG

Best Penny Stocks to Buy Right Now? 3 to Watch in October

Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now?

11:04 26 Feb 2024 EYEG

Penny Stocks For Your Biotech Watch List In September 2021

Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:21 26 Feb 2024 EYEG

4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%

Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:15 26 Feb 2024 EYEG

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

06:55 26 Feb 2024 EYEG

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

01:00 26 Feb 2024 EYEG

Top Penny Stocks You Need to Know About Right Now

Are these top penny stocks on your small-caps watchlist The post Top Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:15 26 Feb 2024 EYEG

EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities.

07:36 26 Feb 2024 EYEG

EYEG Stock Price Falls Over 14% Pre-Market: Why It Happened

The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) fell by over 14% pre-market. This is why it happened.

EYEG Financial details

Company Rating
Neutral
Market Cap
65.45M
Income
-10.43M
Revenue
12.06K
Book val./share
2.46
Cash/share
1.57
Dividend
0.09
Dividend %
0.26%
Employees
14
Optionable
No
Shortable
Yes
Earnings
08 Nov 2021
P/E
-14.06
Forward P/E
-
PEG
5.6
P/S
17444270044.2
P/B
16.25
P/C
22.55
P/FCF
-8.88
Quick Ratio
0.72
Current Ratio
1.02
Debt / Equity
0.47
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.67
EPS next Y
-
EPS next Q
-
EPS this Y
13.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-35.45%
Revenue last 5Y
-55.21%
Revenue Q/Q
-
EPS Q/Q
20%
-
-
-
-
SMA20
-0.59%
SMA50
-
SMA100
-
Inst Own
8.45%
Inst Trans
0.16%
ROA
-53%
ROE
-119%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-68105%
Profit Margin
-67103%
Payout
-
Shs Outstand
1.85M
Shs Float
965.32K
-
-
-
-
Target Price
-
52W Range
35.0654-36.2422
52W High
-1.67%
52W Low
+1.14%
RSI
41.31
Rel Volume
-
Avg Volume
190
Volume
Perf Week
-0.07%
Perf Month
-1.17%
Perf Quarter
-
Perf Half Y
-0.53%
-
-
-
-
Beta
0.797402
-
-
Volatility
0.19%, 0.21%
Prev Close
-1.72%
Price
35.4005
Change
-1.72%

EYEG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.140.430.70.840
Net income per share
-22.66-13.9-4.57-2.23-2.54
Operating cash flow per share
-14.29-6.8-4.58-2.56-2.3
Free cash flow per share
-14.3-6.84-4.7-2.56-2.34
Cash per share
6.178.213.381.190.37
Book value per share
-0.56-2.033.782.082.2
Tangible book value per share
-9.79-7.751.380.3-1.95
Share holders equity per share
-0.56-2.033.782.082.2
Interest debt per share
0.020.0100.030.1
Market cap
14.4M15.26M16.5M31.87M15.68M
Enterprise value
10.79M7.47M8.5M28.18M14.82M
P/E ratio
-1.08-1.15-1.53-4.49-1.94
Price to sales ratio
21.5237.449.9911.871.3K
POCF ratio
-1.71-2.36-1.52-3.91-2.14
PFCF ratio
-1.71-2.35-1.48-3.91-2.1
P/B Ratio
-43.71-7.921.854.812.24
PTB ratio
-43.71-7.921.854.812.24
EV to sales
16.1318.335.1510.491.23K
Enterprise value over EBITDA
-0.81-0.51-0.8-4.15-1.84
EV to operating cash flow
-1.28-1.15-0.78-3.46-2.03
EV to free cash flow
-1.28-1.15-0.77-3.46-1.99
Earnings yield
-0.93-0.87-0.66-0.22-0.52
Free cash flow yield
-0.59-0.43-0.67-0.26-0.48
Debt to equity
-30.54-8.420.60.531.17
Debt to assets
1.031.130.370.350.54
Net debt to EBITDA
0.270.540.750.540.11
Current ratio
0.570.572.193.061.02
Interest coverage
-48.53K-11.98K-10.43K-21.87K-1.96K
Income quality
0.630.4911.150.9
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
8.3611.382.691.64386.33
Research and developement to revenue
12.5825.354.872.01295.72
Intangibles to total assets
0.560.380.40.560.87
Capex to operating cash flow
00.010.0200.02
Capex to revenue
-0.02-0.09-0.160-11.09
Capex to depreciation
-2.12-1.92-7.020-4.01
Stock based compensation to revenue
0.762.140.530.3260.03
Graham number
16.8925.1819.7110.2211.22
ROIC
-12.746.576.1-3.07-0.67
Return on tangible assets
-3.11-1.49-1.26-1.59-4.17
Graham Net
-10.84-8.841.130.09-2.17
Working capital
-3.15M-6.37M4.61M2.91M37.82K
Tangible asset value
-5.77M-7.37M3.25M965.5K-6.22M
Net current asset value
-5.91M-7.77M3.13M834.25K-6.35M
Invested capital
-0.04-0.0100.010.05
Average receivables
493.21K38.76K21.06K11.65K47.92K
Average payables
914.91K1.06M384.87K136.97K322.53K
Average inventory
00000
Days sales outstanding
29.3621.214.070.662.75K
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
12.4317.2189.64553.020.13
Payables turnover
00000
Inventory turnover
00000
ROE
40.516.86-1.21-1.07-1.16
Capex per share
-0.02-0.04-0.110-0.04

Quarterly Fundamentals Overview

Last date of statement is 2021-09-30 for Q3

Metric History 2020-09-302020-12-312021-03-312021-06-30 2021-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.44-0.53-0.37-0.35-0.42
Operating cash flow per share
-0.38-0.38-0.37-0.37-0.32
Free cash flow per share
-0.38-0.41-0.38-0.37-0.32
Cash per share
0.640.260.950.521.57
Book value per share
1.311.541.821.482.46
Tangible book value per share
0.07-1.37-0.08-0.390.59
Share holders equity per share
1.311.541.821.482.46
Interest debt per share
0.070.070.080.040.07
Market cap
17.83M22.42M34.63M25.71M15.89M
Enterprise value
15.23M21.56M28.54M22.35M5.3M
P/E ratio
-2.22-2.32-3.35-2.6-1.34
Price to sales ratio
01.86K000
POCF ratio
-10.24-13.11-13.48-9.75-7
PFCF ratio
-10.24-12.16-13.18-9.73-7
P/B Ratio
2.993.22.732.460.92
PTB ratio
2.993.22.732.460.92
EV to sales
01.79K000
Enterprise value over EBITDA
-7.62-8.97-11.11-9.11-1.79
EV to operating cash flow
-8.75-12.61-11.11-8.48-2.34
EV to free cash flow
-8.75-11.7-10.86-8.46-2.34
Earnings yield
-0.11-0.11-0.07-0.1-0.19
Free cash flow yield
-0.1-0.08-0.08-0.1-0.14
Debt to equity
0.551.170.630.730.47
Debt to assets
0.360.540.380.420.32
Net debt to EBITDA
1.30.362.371.373.58
Current ratio
3.761.024.93.076.06
Interest coverage
0-600.45-3.76K-1.35K0
Income quality
0.870.7111.070.77
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0125.59000
Research and developement to revenue
083.84000
Intangibles to total assets
0.610.870.640.730.52
Capex to operating cash flow
00.010.0200
Capex to revenue
0-1.66000
Capex to depreciation
0-2.22-5.48-0.460
Stock based compensation to revenue
016.02000
Graham number
3.614.293.93.414.82
ROIC
-0.6-0.2-0.37-0.26-1.04
Return on tangible assets
-0.56-1.24-0.35-0.5-0.24
Graham Net
-0.08-1.52-0.17-0.530.42
Working capital
2.57M37.82K5.57M2.98M9.91M
Tangible asset value
323.14K-6.22M-523.52K-2.75M4.15M
Net current asset value
213.86K-6.35M-944.52K-3.23M3.72M
Invested capital
0.060.050.040.030.03
Average receivables
2.15K46.87K119.04K229.14K155.58K
Average payables
76.91K247.15K446.06K374.83K358.6K
Average inventory
00000
Days sales outstanding
0678.97000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00.13000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.34-0.35-0.2-0.24-0.17
Capex per share
00-0.0100

EYEG Frequently Asked Questions

What is EyeGate Pharmaceuticals, Inc. stock symbol ?

EyeGate Pharmaceuticals, Inc. is a US stock , located in Waltham of Massachusetts and trading under the symbol EYEG

What is EyeGate Pharmaceuticals, Inc. stock quote today ?

EyeGate Pharmaceuticals, Inc. stock price is $35.4005 today.

Is EyeGate Pharmaceuticals, Inc. stock public?

Yes, EyeGate Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap